Covid-19 challenges US dreams for Copenhagen-based diagnostics company

In spite of Covid-19, the plans to launch in the US in 2020 is still on the table for Radiobiotics, which develops algorithms for detecting diseases on X-ray scans. The firm has entered into a new US partnership, and before the new year, it will submit an FDA application and kick off the commercialization process.

From the left: CTO Pavel Lisouski, COO Stine Mølgaard Sørensen, CEO Mads Jarner Brevadt and CSO Martin Axelsen. All co-founders of Radiobiotics. Photo: Radiobotics / PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles